{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:09:42Z","timestamp":1792501782207,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies, with limited efficacy of systemic therapies due to poor survival benefit and drug resistance. Dolichyl-diphosphooligosaccharide-protein glycosyltransferase noncatalytic subunit (DDOST), a critical component of oligosaccharyltransferase (OST), is upregulated in multiple cancers, yet its role in HCC is unclear. Here we demonstrate that DDOST expression is elevated in HCC tissues and correlated with poor prognosis. Functional studies showed that\n                    <jats:italic>DDOST<\/jats:italic>\n                    knockdown suppressed cell proliferation, induced cell cycle arrest and enhanced their lenvatinib sensitivity both in vitro and in vivo. Mechanistically, DDOST depletion impaired EGFR N-glycosylation, suppressing downstream AKT, ERK5 and ERK1\/2 signaling, thereby sensitizing HCC cells to lenvatinib. Loss of DDOST also reduced PD-L1 glycosylation. Furthermore, the OST inhibitor NGI-1 and NGI-1-loaded nanoparticles exerted potent antitumor effects and further augmented the efficacy of lenvatinib and immunotherapy. These findings highlight DDOST as a promising therapeutic target to improve treatment outcomes in HCC.\n                  <\/jats:p>","DOI":"10.1038\/s12276-025-01597-9","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:02:10Z","timestamp":1766102530000},"page":"2869-2885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma"],"prefix":"10.1038","volume":"57","author":[{"given":"Jun","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7010-7944","authenticated-orcid":false,"given":"Peng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiju","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"1597_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"1597_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA: Cancer J. Clin."},{"key":"1597_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11938-021-00346-x","volume":"19","author":"TT Ghaziani","year":"2021","unstructured":"Ghaziani, T. T. & Dhanasekaran, R. Recent progress in systemic therapy for hepatocellular cancer (HCC). Curr. Opin. Gastroenterol. 19, 351\u2013368 (2021).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"1597_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1597_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1597_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.gendis.2020.03.010","volume":"7","author":"XD Zhu","year":"2020","unstructured":"Zhu, X. D., Tang, Z. Y. & Sun, H. C. Targeting angiogenesis for liver cancer: past, present, and future. Genes Dis. 7, 328\u2013335 (2020).","journal-title":"Genes Dis."},{"key":"1597_CR7","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y., Zhang, Y.-N., Wang, K.-T. & Chen, L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim. Biophys. Acta Rev. Cancer 1874, 188391 (2020).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1597_CR8","first-page":"649","volume":"6","author":"A Vogel","year":"2021","unstructured":"Vogel, A. et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Gastroenterol. Hepatol. 6, 649\u2013658 (2021).","journal-title":"Gastroenterol. Hepatol."},{"key":"1597_CR9","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","volume":"84","author":"Y Ito","year":"2001","unstructured":"Ito, Y. et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 84, 1377\u20131383 (2001).","journal-title":"Br. J. Cancer"},{"key":"1597_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12076-w","volume":"12","author":"X He","year":"2022","unstructured":"He, X. et al. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. Sci. Rep. 12, 8007 (2022).","journal-title":"Sci. Rep."},{"key":"1597_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730\u2013734 (2021).","journal-title":"Nature"},{"key":"1597_CR12","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"Hu, B. et al. Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3\u2013ABCB1 signaling in hepatocellular carcinoma. Cancer Res. 82, 3845\u20133857 (2022).","journal-title":"Cancer Res."},{"key":"1597_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ceb.2016.03.021","volume":"41","author":"N Cherepanova","year":"2016","unstructured":"Cherepanova, N., Shrimal, S. & Gilmore, R. N-linked glycosylation and homeostasis of the endoplasmic reticulum. Curr. Opin. Cell Biol. 41, 57\u201365 (2016).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1597_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/ijms19020580","volume":"19","author":"IG Ferreira","year":"2018","unstructured":"Ferreira, I. G. et al. Glycosylation as a main regulator of growth and death factor receptors signaling. Int. J. Mol. Sci. 19, 580 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1597_CR15","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.1074\/jbc.M005599200","volume":"276","author":"H Fernandes","year":"2001","unstructured":"Fernandes, H., Cohen, S. & Bishayee, S. Glycosylation-induced conformational modification positively regulates receptor\u2013receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII\/DeltaEGFR) expressed in cancer cells. J. Biol. Chem. 276, 5375\u20135383 (2001).","journal-title":"J. Biol. Chem."},{"key":"1597_CR16","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1158\/0008-5472.CAN-07-6389","volume":"68","author":"JN Contessa","year":"2008","unstructured":"Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A. & Lawrence, T. S. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 68, 3803\u20133809 (2008).","journal-title":"Cancer Res."},{"key":"1597_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li, C. W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).","journal-title":"Nat. Commun."},{"key":"1597_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","volume":"36","author":"HH Lee","year":"2019","unstructured":"Lee, H. H. et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy. Cancer Cell 36, 168\u2013178 (2019).","journal-title":"Cancer Cell"},{"key":"1597_CR19","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"1597_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940\u2013952 (2018).","journal-title":"Lancet Oncol."},{"key":"1597_CR21","first-page":"1837","volume":"8","author":"B Shao","year":"2018","unstructured":"Shao, B. et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Am. J. Cancer Res. 8, 1837\u20131846 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"1597_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","volume":"71","author":"JH Cha","year":"2018","unstructured":"Cha, J. H. et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol. Cell 71, 606\u2013620.e607 (2018).","journal-title":"Mol. Cell"},{"key":"1597_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.18632\/aging.102646","volume":"12","author":"S Verdura","year":"2020","unstructured":"Verdura, S. et al. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging 12, 8\u201334 (2020).","journal-title":"Aging"},{"key":"1597_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/mc.23170","volume":"59","author":"B Kim","year":"2020","unstructured":"Kim, B. et al. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation. Mol. Carcinog. 59, 691\u2013700 (2020).","journal-title":"Mol. Carcinog."},{"key":"1597_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04313-6","volume":"9","author":"JM Hsu","year":"2018","unstructured":"Hsu, J. M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018).","journal-title":"Nat. Commun."},{"key":"1597_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09752-3","volume":"10","author":"ST Li","year":"2019","unstructured":"Li, S. T. et al. Reconstitution of the lipid-linked oligosaccharide pathway for assembly of high-mannose N-glycans. Nat. Commun. 10, 1813 (2019).","journal-title":"Nat. Commun."},{"key":"1597_CR27","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.3390\/ijms20236074","volume":"20","author":"Y Harada","year":"2019","unstructured":"Harada, Y., Ohkawa, Y., Kizuka, Y. & Taniguchi, N. Oligosaccharyltransferase: a gatekeeper of health and tumor progression. Int. J. Mol. Sci. 20, 6074 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1597_CR28","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1172\/JCI126022","volume":"129","author":"LC Chan","year":"2019","unstructured":"Chan, L. C. et al. IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J. Clin. Invest. 129, 3324\u20133338 (2019).","journal-title":"J. Clin. Invest."},{"key":"1597_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nchembio.2194","volume":"12","author":"C Lopez-Sambrooks","year":"2016","unstructured":"Lopez-Sambrooks, C. et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat. Chem. Biol. 12, 1023\u20131030 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"1597_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.815437","volume":"12","author":"XM Ma","year":"2022","unstructured":"Ma, X. M. et al. TGF-beta1-mediated PD-L1 glycosylation contributes to immune escape via c-Jun\/STT3A pathway in nasopharyngeal carcinoma. Front. Oncol. 12, 815437 (2022).","journal-title":"Front. Oncol."},{"key":"1597_CR31","doi-asserted-by":"publisher","first-page":"917014","DOI":"10.3389\/fimmu.2022.917014","volume":"13","author":"X Chang","year":"2022","unstructured":"Chang, X. et al. DDOST correlated with malignancies and immune microenvironment in gliomas. Front. Immunol. 13, 917014 (2022).","journal-title":"Front. Immunol."},{"key":"1597_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjd.19485","volume":"184","author":"A Shapanis","year":"2021","unstructured":"Shapanis, A. et al. Identification of proteins associated with development of metastasis from cutaneous squamous cell carcinomas (cSCCs) via proteomic analysis of primary cSCCs. Br. J. Dermatol. 184, 709\u2013721 (2021).","journal-title":"Br. J. Dermatol."},{"key":"1597_CR33","doi-asserted-by":"publisher","first-page":"722624","DOI":"10.3389\/fonc.2021.722624","volume":"11","author":"J Ding","year":"2021","unstructured":"Ding, J. et al. Knockdown of oligosaccharyltransferase subunit ribophorin 1 induces endoplasmic-reticulum-stress-dependent cell apoptosis in breast cancer. Front. Oncol. 11, 722624 (2021).","journal-title":"Front. Oncol."},{"key":"1597_CR34","doi-asserted-by":"publisher","first-page":"819520","DOI":"10.3389\/fgene.2021.819520","volume":"12","author":"C Zhu","year":"2021","unstructured":"Zhu, C., Xiao, H., Jiang, X., Tong, R. & Guan, J. Prognostic biomarker DDOST and its correlation with immune infiltrates in hepatocellular carcinoma. Front. Genet. 12, 819520 (2021).","journal-title":"Front. Genet."},{"key":"1597_CR35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fgene.2019.01245","volume":"10","author":"M Hu","year":"2019","unstructured":"Hu, M. et al. Identification of differently expressed genes associated with prognosis and growth in colon adenocarcinoma based on integrated bioinformatics analysis. Front. Genet. 10, 1245 (2019).","journal-title":"Front. Genet."},{"key":"1597_CR36","doi-asserted-by":"publisher","first-page":"e1010989","DOI":"10.1371\/journal.ppat.1010989","volume":"18","author":"C Lu","year":"2022","unstructured":"Lu, C. et al. MITA oligomerization upon viral infection is dependent on its N-glycosylation mediated by DDOST. PLoS Pathog. 18, e1010989 (2022).","journal-title":"PLoS Pathog."},{"key":"1597_CR37","first-page":"613","volume":"102","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Positive feedback loops between NrCAM and major signaling pathways contribute to thyroid tumorigenesis. J. Clin. Endocrinol. Metab. 102, 613\u2013624 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1597_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13046-021-02195-z","volume":"40","author":"S Ma","year":"2021","unstructured":"Ma, S. et al. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase. J. Exp. Clin. Cancer Res. 40, 387 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1597_CR39","doi-asserted-by":"publisher","first-page":"151973","DOI":"10.1016\/j.cej.2024.151973","volume":"491","author":"X Lan","year":"2024","unstructured":"Lan, X. et al. Lung-targeted delivery of nsp12 siRNAs restores host type I interferon responses. Chem. Eng. J. 491, 151973 (2024).","journal-title":"Chem. Eng. J."},{"key":"1597_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1089\/thy.2018.0312","volume":"29","author":"N Wang","year":"2019","unstructured":"Wang, N. et al. TBX1 functions as a tumor suppressor in thyroid cancer through inhibiting the activities of the PI3K\/AKT and MAPK\/ERK pathways. Thyroid 29, 378\u2013394 (2019).","journal-title":"Thyroid"},{"key":"1597_CR41","first-page":"4866","volume":"11","author":"J Pu","year":"2021","unstructured":"Pu, J., Zhou, X., Liu, J., Hou, P. & Ji, M. Therapeutic potential and deleterious effect of glucocorticoids on azoxymethane\/dextran sulfate sodium-induced colorectal cancer in mice. Am. J. Cancer Res. 11, 4866\u20134883 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"1597_CR42","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1158\/0008-5472.CAN-18-0505","volume":"78","author":"C Lopez Sambrooks","year":"2018","unstructured":"Lopez Sambrooks, C. et al. Oligosaccharyltransferase inhibition overcomes therapeutic resistance to EGFR tyrosine kinase inhibitors. Cancer Res. 78, 5094\u20135106 (2018).","journal-title":"Cancer Res."},{"key":"1597_CR43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12951-021-01034-9","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment. J. Nanobiotechnol. 19, 302 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"1597_CR44","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm.1858","volume":"14","author":"K Honma","year":"2008","unstructured":"Honma, K. et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 14, 939\u2013948 (2008).","journal-title":"Nat. Med."},{"key":"1597_CR45","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-023-42178-y","volume":"13","author":"SM Kas","year":"2023","unstructured":"Kas, S. M., Mundra, P. A., Smith, D. L. & Marais, R. Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylation. Sci. Rep. 13, 17648 (2023).","journal-title":"Sci. Rep."},{"key":"1597_CR46","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1242\/jcs.094599","volume":"125","author":"P Roboti","year":"2012","unstructured":"Roboti, P. & High, S. The oligosaccharyltransferase subunits OST48, DAD1 and KCP2 function as ubiquitous and selective modulators of mammalian N-glycosylation. J. Cell Sci. 125, 3474\u20133484 (2012).","journal-title":"J. Cell Sci."},{"key":"1597_CR47","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-09-3331","volume":"16","author":"JN Contessa","year":"2010","unstructured":"Contessa, J. N. et al. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin. Cancer Res. 16, 3205\u20133214 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1597_CR48","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1042\/CS20160273","volume":"130","author":"M Takahashi","year":"2016","unstructured":"Takahashi, M., Hasegawa, Y., Gao, C., Kuroki, Y. & Taniguchi, N. N-glycans of growth factor receptors: Their role in receptor function and disease implications. Clin. Sci. 130, 1781\u20131792 (2016).","journal-title":"Clin. Sci."},{"key":"1597_CR49","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1073\/pnas.1503262112","volume":"112","author":"K Kaszuba","year":"2015","unstructured":"Kaszuba, K. et al. N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Proc. Natl Acad. Sci. USA 112, 4334\u20134339 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1597_CR50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/prot.25314","volume":"85","author":"M Azimzadeh Irani","year":"2017","unstructured":"Azimzadeh Irani, M., Kannan, S. & Verma, C. Role of N-glycosylation in EGFR ectodomain ligand binding. Proteins Struct. Funct. Bioinf. 85, 1529\u20131549 (2017).","journal-title":"Proteins Struct. Funct. Bioinf."},{"key":"1597_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","volume":"27","author":"YN Wang","year":"2020","unstructured":"Wang, Y. N., Lee, H. H., Hsu, J. L., Yu, D. & Hung, M. C. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J. Biomed. Sci. 27, 77 (2020).","journal-title":"J. Biomed. Sci."},{"key":"1597_CR52","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.chembiol.2018.07.005","volume":"25","author":"N Rinis","year":"2018","unstructured":"Rinis, N. et al. Editing N-glycan site occupancy with small-molecule oligosaccharyltransferase inhibitors. Cell Chem. Bio. 25, 1231\u20131241 (2018).","journal-title":"Cell Chem. Bio."},{"key":"1597_CR53","doi-asserted-by":"publisher","first-page":"990505","DOI":"10.3389\/fphar.2022.990505","volume":"13","author":"D Zhang","year":"2022","unstructured":"Zhang, D. et al. Drug-loaded PEG-PLGA nanoparticles for cancer treatment. Front. Pharmacol. 13, 990505 (2022).","journal-title":"Front. Pharmacol."},{"key":"1597_CR54","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1002\/agt2.545","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Smart multi-functional aggregates reoxygenate tumor microenvironment through a two-pronged strategy to revitalize cancer immunotherapy. Aggregate. 5, e545 (2024).","journal-title":"Aggregate."},{"key":"1597_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/toxsci\/kfy185","volume":"165","author":"AD Patterson","year":"2018","unstructured":"Patterson, A. D., Gonzalez, F. J., Perdew, G. H. & Peters, J. M. Molecular regulation of carcinogenesis: friend and foe. Toxicol. Sci. 165, 277\u2013283 (2018).","journal-title":"Toxicol. Sci."},{"key":"1597_CR56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.trecan.2020.04.002","volume":"6","author":"AF Costa","year":"2020","unstructured":"Costa, A. F., Campos, D., Reis, C. A. & Gomes, C. Targeting glycosylation: a new road for cancer drug discovery. Trends Cancer 6, 757\u2013766 (2020).","journal-title":"Trends Cancer"},{"key":"1597_CR57","doi-asserted-by":"publisher","first-page":"188464","DOI":"10.1016\/j.bbcan.2020.188464","volume":"1875","author":"D Thomas","year":"2021","unstructured":"Thomas, D., Rathinavel, A. K. & Radhakrishnan, P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochim. Biophys. Acta Rev. Cancer 1875, 188464 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1597_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/cancers12010239","volume":"12","author":"L Santorelli","year":"2020","unstructured":"Santorelli, L. et al. In-depth mapping of the urinary N-glycoproteome: distinct signatures of ccRCC-related progression. Cancers 12, 239 (2020).","journal-title":"Cancers"},{"key":"1597_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34534-0","volume":"8","author":"M Napiorkowska","year":"2018","unstructured":"Napiorkowska, M., Boilevin, J., Darbre, T., Reymond, J. L. & Locher, K. P. Structure of bacterial oligosaccharyltransferase PglB bound to a reactive LLO and an inhibitory peptide. Sci. Rep. 8, 16297 (2018).","journal-title":"Sci. Rep."},{"key":"1597_CR60","doi-asserted-by":"publisher","first-page":"jcs243790","DOI":"10.1242\/jcs.243790","volume":"133","author":"JD Knopf","year":"2020","unstructured":"Knopf, J. D. et al. Intramembrane protease RHBDL4 cleaves oligosaccharyltransferase subunits to target them for ER-associated degradation. J. Cell Sci. 133, jcs243790 (2020).","journal-title":"J. Cell Sci."},{"key":"1597_CR61","doi-asserted-by":"crossref","unstructured":"Tominaga, N., Hagiwara, K., Kosaka, N., Honma, K. & Ochiya, T. RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. Mol. Cancer 13, 134 (2014).","DOI":"10.1186\/1476-4598-13-134"},{"key":"1597_CR62","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.12659\/MSM.909514","volume":"24","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y., Fang, L., Zang, Y. & Xu, Z. Identification of core genes and key pathways via integrated analysis of gene expression and DNA methylation profiles in bladder cancer. Med. Sci. Monit. 24, 3024\u20133033 (2018).","journal-title":"Med. Sci. Monit."},{"key":"1597_CR63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","volume":"36","author":"S Mereiter","year":"2019","unstructured":"Mereiter, S., Balmana, M., Campos, D., Gomes, J. & Reis, C. A. Glycosylation in the era of cancer-targeted therapy: where are we heading?. Cancer Cell 36, 6\u201316 (2019).","journal-title":"Cancer Cell"},{"key":"1597_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04796-8","volume":"13","author":"S Song","year":"2022","unstructured":"Song, S. et al. EGFR\/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli. Cell Death Dis. 13, 351 (2022).","journal-title":"Cell Death Dis."},{"key":"1597_CR65","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1111\/cas.15465","volume":"113","author":"K Ohno","year":"2022","unstructured":"Ohno, K., Shibata, T. & Ito, K. -i Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Sci. 113, 3193\u20133210 (2022).","journal-title":"Cancer Sci."},{"key":"1597_CR66","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.7150\/ijbs.69969","volume":"18","author":"S Huang","year":"2022","unstructured":"Huang, S. et al. Genome-wide CRISPR\/Cas9 library screening identified that DUSP4 deficiency induces lenvatinib resistance in hepatocellular carcinoma. Int. J. Biol. Sci. 18, 4357\u20134371 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"1597_CR67","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jcmm.16108","volume":"25","author":"Z Zhao","year":"2021","unstructured":"Zhao, Z. et al. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS\/MEK\/ERK axis via decreasing VEGFR2 expression. J. Cell. Mol. Med. 25, 549\u2013560 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"1597_CR68","doi-asserted-by":"publisher","first-page":"944537","DOI":"10.3389\/fonc.2022.944537","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Liu, J., Wang, Y. & Dong, J. Co-administration of MDR1 and BCRP or EGFR\/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Front. Oncol. 12, 944537 (2022).","journal-title":"Front. Oncol."},{"key":"1597_CR69","doi-asserted-by":"publisher","first-page":"e2411740","DOI":"10.1002\/advs.202411740","volume":"12","author":"N Xiong","year":"2024","unstructured":"Xiong, N. et al. N-glycosylation modification of CTSD affects liver metastases in colorectal cancer. Adv. Sci. 12, e2411740 (2024).","journal-title":"Adv. Sci."},{"key":"1597_CR70","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/2159-8290.CD-20-0402","volume":"10","author":"X Song","year":"2020","unstructured":"Song, X. et al. Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. Cancer Discov. 10, 1872\u20131893 (2020).","journal-title":"Cancer Discov."},{"key":"1597_CR71","doi-asserted-by":"publisher","first-page":"216819","DOI":"10.1016\/j.canlet.2024.216819","volume":"589","author":"D Zhang","year":"2024","unstructured":"Zhang, D. et al. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer. Cancer Lett. 589, 216819 (2024).","journal-title":"Cancer Lett."},{"key":"1597_CR72","doi-asserted-by":"publisher","first-page":"899192","DOI":"10.3389\/fmolb.2022.899192","volume":"9","author":"X Cao","year":"2022","unstructured":"Cao, X. et al. Nascent glycoproteome reveals that N-linked glycosylation inhibitor-1 suppresses expression of glycosylated lysosome-associated membrane protein-2. Front. Mol. Biosci. 9, 899192 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"1597_CR73","unstructured":"Ddost | dolichyl-di-phosphooligosaccharide-protein glycotransferase. International Mouse Phenotyping Consortium https:\/\/www.mousephenotype.org\/data\/genes\/MGI:1194508 (2025)."},{"key":"1597_CR74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature19356","volume":"537","author":"ME Dickinson","year":"2016","unstructured":"Dickinson, M. E. et al. High-throughput discovery of novel developmental phenotypes. Nature 537, 508\u2013514 (2016).","journal-title":"Nature"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01597-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01597-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01597-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:02:19Z","timestamp":1768323739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01597-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":74,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01597-9","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Laboratory Animal Center of Xi\u2019an Jiaotong University (approval number XJTUAE2024-766) and conducted on the basis of the institutional guidelines. In addition, this study was approved by the Institutional Review Board, Human Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University (approval number G-63).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study approval"}}]}}